Appreciate the conversation advancement there.
The shouting and profanity was becoming tiring
In regard to the first point, I believe success here will demonstrate a case for complimentary use cases. I also wonder if the market segmentation and delivery method,.portability, tolerance etc will ultimately be as relevant as end efficacy.
Legal technicality re the latter, and I gather its more complex then will be presumed either way here, but it would seem counter-intuitive to me to provide IP 'coverage' to facilitate medical advances in recognition of the cost and difficulty of development. See demonstrated progress then decline extension... cant see it logically
BIT036- a likely candidate for curing COVID-19, page-1923
Add BIT (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
5.2¢ |
Change
-0.003(5.45%) |
Mkt cap ! $46.91M | |||
| Open | High | Low | Value | Volume |
| 5.4¢ | 5.4¢ | 5.2¢ | $9.625K | 180.7K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 38 | 5.4¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 5.7¢ | 43999 | 1 |
View Market Depth
| Last trade - 13.47pm 21/05/2024 (20 minute delay) ? |
|
|||||
|
Last
5.2¢ |
Change
-0.003 ( 7.14 %) |
||||
| Open | High | Low | Volume | ||
| 5.6¢ | 5.6¢ | 5.2¢ | 76305 | ||
| Last updated 13.47pm 21/05/2024 ? | |||||
| BIT (ASX) Chart |